SCHEMBL51542

SCHEMBL51542

Cc1ccc(S(N)(=O)=O)nc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 8/20 0.61
CA2 P00918 8/20 0.61
CA9 Q16790 8/20 0.61
CA12 O43570 7/20 0.61
CA6 P23280 3/20 0.61
CA5A P35218 3/20 0.61
CA7 P43166 3/20 0.61
CA4 P22748 2/20 0.61
CA13 Q8N1Q1 2/20 0.61
CA14 Q9ULX7 2/20 0.61
NOS3 P29474 1/20 0.46
NOS2 P35228 1/20 0.46
CA3 P07451 1/20 0.46
CA5B Q9Y2D0 1/20 0.46
CCR1 P32246 1/20 0.44
CCR5 P51681 1/20 0.44
CCR8 P51685 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
SLC40A1 Q9NP59 1/20 0.42
PTGS2 P35354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28312398 0.98 CA12 (0.59) CA1CA2CA9CA12CA6
SCHEMBL31527849 0.98 CA12 (0.59) CA1CA2CA9CA12CA6
Potassium SCHEMBL6789782 0.98 CA12 (0.59) CA1CA2CA9CA12CA6
SCHEMBL6789774 0.98 CA12 (0.59) CA1CA2CA9CA12CA6
SCHEMBL486163 0.80 CCR1 (0.46) CA1CA2CA9CA12CA6
SCHEMBL29733038 0.78 CCR1 (0.50) CA1CA2CA9CA12CA6
SCHEMBL2633881 0.78 CCR1 (0.50) CA1CA2CA9CA12CA6
SCHEMBL1038893 0.78 CCR1 (0.44) CA1CA2CA9CA12CA6
SCHEMBL22792202 0.77 CCR1 (0.43) CA1CA2CA9CA12CA6
Hydrochloric Acid SCHEMBL28104938 0.77 CCR1 (0.48) CA1CA2CA9CA12CA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4721742-A2 CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Idorsia Pharmaceuticals Ltd (CH) 2026-04-08 EP claimed
EP-4582086-A2 CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Idorsia Pharmaceuticals Ltd (CH) 2025-07-09 EP claimed
CN-119569647-A Buried material compound and application thereof in perovskite battery 厦门紫金新能源新材料科技有限公司 2025-03-07 CN claimed
US-20250051308-A1 CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME IDORSIA PHARMACEUTICALS LTD (CH) 2025-02-13 US claimed
EP-4448511-A1 CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Idorsia Pharmaceuticals Ltd (CH) 2024-10-23 EP claimed
WO-2023111299-A1 CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME IDORSIA PHARMACEUTICALS LTD (CH) 2023-06-22 WO claimed
US-11471455-B2 Compounds and compositions for treating conditions associated with APJ receptor activity ANNAPURNA BIO, INC. (US) 2022-10-18 US claimed
EP-0897914-B1 Process for the preparation of 2,5-disubstitued pyridines HOFFMANN LA ROCHE (CH) 2004-05-26 EP claimed
US-6080866-A A CHEMICAL INTERMEDIATES FOR ENDOTHELIN RECEPTOR ANTAGONISTS HOFFMANN-LA ROCHE INC. (US) 2000-06-27 US claimed
CN-1210105-A Process for preparation of 2,5-disubstituted pyridines HOFFMANN LA ROCHE (CH) 1999-03-10 CN claimed
EP-0897914-A1 Process for the preparation of 2,5-disubstitued pyridines F. HOFFMANN-LA ROCHE AG (CH) 1999-02-24 EP claimed
EP-4721742-A2 CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME Idorsia Pharmaceuticals Ltd (CH) 2026-04-08 EP disclosed
US-12551475-B2 Methods and compositions for treating RNA viral infections MODEL MEDICINES, INC. (US) 2026-02-17 US disclosed
US-20260001886-A1 ENPP1 INHIBITORS I RE VENTURES I LLC (US) 2026-01-01 US disclosed
EP-4667008-A2 METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS Model Medicines, Inc. (US) 2025-12-24 EP disclosed
US-5837708-A CARDIOVASCULAR DISORDERS OF HYPERTENSION, ISCHEMIA, ANGINA PECTORIS AND VASOSPASMS HOFFMANN-LA ROCHE INC. (US) 1998-11-17 US disclosed
WO-1997043260-A1 INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS PFIZER INC. (US) 1997-11-20 WO disclosed
CN-1132751-A Novel sulfonamides compound and its use as medicine HOFFMANN LA ROCHE (CH) 1996-10-09 CN disclosed
WO-1996016963-A1 SULFONAMIDES AND THEIR USE AS MEDICAMENTS F. HOFFMANN-LA ROCHE AG (CH) 1996-06-06 WO disclosed
EP-0713875-A1 Sulfonamides F. Hoffmann-La Roche AG (CH) 1996-05-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12551475-B2 Methods and compositions for treating RNA viral infections SARS1, EIF2AK2, SNRPE CA1 4643/4885CA2 1822/4885CA9 2475/4885
US-20250051308-A1 CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME SSTR5, SSTR3, TACR1 CA1 424/4885CA2 151/4885CA9 184/4885
US-20260001886-A1 ENPP1 INHIBITORS I ENPP1, ENPP2, ENPP3 CA1 4636/4885CA2 3450/4885CA9 4472/4885
US-11471455-B2 Compounds and compositions for treating conditions associated with APJ receptor activity APLNR, AGTR1, AGTR2 CA1 3132/4885CA2 962/4885CA9 635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.